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INTRODUCTION
Over the last two decades, different hormones, en-
zymes and other proteins have appeared as markers for
cardiac problems. In human medicine, one of the most
important applications of these cardiac biomarkers is to
diagnose acute myocardial infarction in patients with
chest pain (Christenson et al., 1998). A number of
these proteins also play an important role in assessing
prognosis in cardiac patients, and the combination of
these individual biomarkers will probably be used in
the future as guidance for therapy; the so-called multi-
marker strategies (Böhm et al., 2011).
Similar to human medicine, a correlation between the
cardiac biomarkers and the prognosis of cardiac disease
has been found in animals (Greco et al., 2003). The re-
cent literature describes the utility of these peptides for
distinguishing cardiac from non-cardiac diseases in small
animals (Fox et al., 2009). These markers have also
found their way in equine cardiology for assessing the se-
verity of heart valve diseases (Trachsel et al., 2011).
This article reviews the most important cardiac biomar-
kers and their use in veterinary, and more particularly,
equine medicine. Although there are many unresolved
questions about the different biomarkers, their future
use to screen cardiac diseases is realistic. 
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ABSTRACT
In human medicine, cardiac biomarkers, such as natriuretic peptides and troponins, are
routinely used for the diagnosis, prognosis and monitoring of heart diseases. Similarly, these
biomarkers are determined in small animals to differentiate non-cardiac from cardiac diseases.
Knowledge about these biomarkers in horses is limited and requires further investigation.
The first equine studies about atrial natriuretic peptide (ANP) and N-terminal ANP (NT-proANP)
are promising, and show a clear correlation with atrial dimension size. Equine brain natriuretic
peptides assays are still unavailable. The troponins, in particular troponin I, have been more
extensively studied in horses, and their use for the diagnosis of myocardial damage has been fully
demonstrated. They have replaced the less specific lactate dehydrogenase and creatine kinase iso-
enzymes, which makes the use of the last mentioned no longer legitimate. A final possible equine
biomarker is aldosterone. Reference values in horses have been established. However, in only one
study, a correlation between aldosterone and cardiac disease has been reported.
SAMENVATTING
Cardiale biomarkers, zoals natriuretische peptiden en troponinen, worden reeds routinematig in de
humane geneeskunde gebruikt voor de diagnose, prognose en monitoring van hartaandoeningen. Hoewel
ze ook in de kleine huisdierensector regelmatig bepaald worden om cardiologische en niet-cardiologische
aandoeningen van elkaar te onderscheiden, is de literatuur omtrent het gebruik bij paarden beperkt.
Bij paarden werd reeds een significante correlatie aangetoond tussen het ‘atrial natriuretic peptide’ (ANP),
N-terminal ANP  (NT-proANP) en de voorkamergrootte. Specifieke equine testen voor ‘brain natriuretic
peptide’ (BNP) of ‘N-terminal BNP’ (NT-proBNP) bepaling ontbreken echter nog steeds. Troponinen
(vooral troponine I) zijn meer uitgebreid bestudeerd bij het paard. Ze worden reeds gebruikt voor de
diagnose van myocardschade en vervangen de minder specifieke lactaatdehydrogenase en creatinekinase
iso-enzymen, waardoor het gebruik van deze laatste niet meer gerechtvaardigd is. Een laatste mogelijk
belangrijke biomarker is aldosteron, maar aangezien slechts één studie bij paarden een correlatie
aangetoond heeft tussen de aldosteronconcentratie en hartaandoeningen is uitgebreider onderzoek nodig. 
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Table 1 summarizes the main cardiac biomarkers
used in human medicine. The troponins and natriuretic
peptides are mostly utilized in daily practice, but also
aldosterone, a hormone of the renin – angiotensin-al-
dosterone system (RAAS) can be measured to evaluate
the cardiac state. 
THE NATRIURETIC PEPTIDES, MARKERS OF
MYOCYTE STRESS
Physiology and structure
In mammals, there are three main natriuretic peptides:
the atrial natriuretic peptides (ANP), the brain natriu-
retic peptides (BNP) and the C-type natriuretic peptide
(CNP). Their main goal is fluid homeostasis. They are
released in case of increased intravascular volume and
thus atrial or ventricular stretch in an attempt to de-
crease cardiac overload by diuresis, natriuresis and va-
sodilatation. Since CNP only causes mild diuresis and
natriuresis, only atrial and brain natriuretic peptides
are used in clinical practice to detect cardiac disease
(Goetze et al., 2003; Takei et al., 2011).
The atrial natriuretic peptides are mostly stored as
pro-hormones (proANP1-126) in numerous granules in
the atrial cardiomyocytes. However, they are also pre-
sent in other organs, such as the pituitary, lungs, hy-
pothalamus and kidneys (Kokkonen et al., 2002; Hayek
and Nemer, 2010). In response to atrial stretch, the pro-
ANP1-126 molecule is split into an inactive NH2-termi-
nal peptide (NT-proANP1-98) and a biologically active
(COOH-terminal) ANP99-126 molecule, which are both
released into the blood stream (Figure 1). After release,
ANP has a short half-life of about 2-5 minutes in hu-
mans. Since the half-life of NT-proANP is longer (55-
60 minutes), NT-proANP can be used to assess endo-
genous secretion of ANP (Thibault et al., 1987;
Ruskoaho, 1992; Kokkonen et al., 2002). The structure
of the ANP-molecules is well conserved, and 100 %
homology exists between the equine and human ANP
(Table 2), which implies that human tests can be used
to measure the ANP concentration in equine blood
(Richter et al., 1998). NT-proANP is more species-spe-
cific with only 80-90% homology between the equine
and the human NT-proANP peptide (Kokkonen, 2002).
Brain natriuretic peptide was first discovered in the
porcine brain. It is currently often called the B-type na-
triuretic peptide because its main production site is ac-
Table 1. Summary of the most important cardiac biomarkers in human medicine. Biomarkers in bold are discussed more
in detail below (adapted from Braunwald, 2008).
Markers of myocyte stress Brain Natriuretic Peptide (BNP)
N-Terminal Pro Brain Natriuretic Peptide (NT-proBNP)
Atrial Natriuretic Peptide (ANP)
N-Terminal Pro Atrial Natriuretic Peptide (NT-proANP)
Midregional proadrenomedullin
ST2
Markers of myocyte injury Troponin T
Troponin I
Creatine kinase MB fraction
Lactate dehydrogenase
Myosin light chain kinase I







Markers of remodeling Matrix metalloproteinases
Tissue inhibitors of matrix metalloproteinases
Collagen propeptides
Markers of inflammation C-Reactive Protein (CRP)
Interleukins 1, 6 and 19
Tumor Necrosis Factor alpha (TNF-α)
Fas (APO-1)
Indirect markers of oxidative stress Oxidized low density lipoproteins
Myeloperoxidase
Urinary biopyrrins
Urinary and plasma isoprostanes
Plasma malondialdehyde
Vlaams Diergeneeskundig Tijdschrift, 2012, 81 321
tually the heart. In contrast to atrial natriuretic peptides,
BNP is more related to ventricular pathological
changes. In healthy individuals, BNP gene expression
occurs mainly in the atria. However, an up-regulation
in the ventricles can be found in people with heart fai-
lure (Goetze, 2004a; Hall, 2005). Similar to the atrial
natriuretic peptides, activation of proBNP1-108 results in
cleavage of this molecule into a biologically inactive
(NT-proBNP1-76) and an active component (BNP77-108)
(Hall, 2005). Both BNP (12.1 min) and NT-proBNP
(120 min) have a longer half-life than the atrial natri-
uretic peptides, which makes them better targets for
diagnostic blood testing (Kemperman et al., 2004; Ki-
mura et al., 2007). 
In comparison with ANP, the B-type peptides are ge-
netically very variable between species (Takei et al.,
2011) (Table 2). Therefore, a human test cannot be used
in veterinary practice. A specific test is available for
small animals (Cardiopet proBNP, IDEXX Vet Med
Lab, Hoofddorp, the Netherlands). However, an equine
test is not available yet. Since there is a gross similarity
(±90% homology) between the equine and the porcine
BNP peptides, a porcine test could potentially be used to
measure the BNP concentration in equine blood (Table
2). The homology between these molecules was first
suggested in 1995, when antibodies against porcine
BNP were utilized for the detection of BNP-like mole-
cules in the equine atria (Mifune et al., 1995). 
Figure 1. Enzymatic cleavage of proANP by corin into NT-proANP and ANP (T1/2 = half-life; min = minutes).
Table 2. Comparison of human, equine, porcine, canine and feline amino-acids sequences of atrial and brain natriuretic
peptides. In contrast to ANP, BNP is very variable between species. The equine B-type natriuretic peptide has a greater
resemblance to the porcine form than the human BNP-molecule. The red-colored amino-acids are species specific (adapted
from Richter et al., 1998; Goetze, 2004; Takei et al., 2011).
Atrial natriuretic peptide
Human S L R R S S C F G G R M D R I G A Q S G L G C N S F R Y
Equine S L R R S S C F G G R M D R I G A Q S G L G C N S F R Y
Porcine S L R R S S C F G G R M D R I G A Q S G L G C N S F R Y
Canine S L R R S S C F G G R M D R I G A Q S G L G C N S F R Y
Feline S L R R S S C F G G R M D R I G A Q S G L G C N S F R Y
Brain natriuretic peptide
Human S P K M V Q G S G C F G R K M D R I S S S S G L G C K V L R
Equine S P K M M R N S G C F G R R L D R I G S F S G L G C N V L R
Porcine S P K T M R D S G C F G R R L D R I G S L S G L G C N V L R
Canine S P K M M H K S G C F G R R L D R I G S L S G L G C N V L R
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The use of natriuretic peptides in human and small
animal veterinary medicine
In human medicine, the brain natriuretic peptides
are frequently used for the diagnosis, prognosis and
therapy monitoring in patients with heart failure. Even
though the atrial natriuretic peptides were discovered
first, nowadays, the B-types are used more often in cli-
nical practice, because of their longer half-life (Wood-
ard and Rosado, 2007). Not only are levels of BNP and
NT-proBNP elevated in cases of heart failure, also
non-cardiac pathologies, such as acute pulmonary em-
bolism, pulmonary hypertension, sepsis or hyperthy-
roidism may influence their concentration (Felker et al.,
2006).
Adjusted BNP and NT-proBNP levels are used in
emergency departments to differentiate between non-
cardiac and cardiac causes of dyspnea (Maisel et al.,
2002; Rogers et al., 2009). Similarly, a species-speci-
fic NT-proBNP test allowed to distinguish acute res-
piratory problems caused by heart failure from non-car-
diac causes in small animals (Fox et al., 2009; Ettinger
et al., 2012). In human medicine, the brain natriuretic
peptides are also used for the detection of myocardial
ischemia in patients with acute coronary syndrome.
Compared with the conventional markers (e.g. tropo-
nin I), the NT-proBNP molecules rise much higher in
an earlier phase, making them more suitable for early
diagnosis (Tsai et al., 2010). Myocardial ischemia is
rare in small animals, but in resemblance to humans a
significant increase in NT-proBNP concentration has
been found in a canine model of myocardial ischemia
(Hori et al., 2012). A much more common disease in
small animals, especially in cats, is hypertrophic cardi-
omyopathy (HCM). Investigation into the use of  NT-
proBNP elevation as screening factor for this disease re-
vealed that it can only be used for the detection of cats
with severe HCM: the NT-proBNP concentration in
cats with moderate or mild HCM is not significantly dif-
ferent from normal individuals (Hsu et al., 2009). 
As mentioned above, the use of atrial natriuretic
peptides in human clinical practice is limited (Saito,
2010). Recently, the diagnostic value of a fragment of
the proANP molecule (mid-region proANP) for heart
failure has been recognized (Ghosh and Haddad, 2011),
and a multi-marker strategy is emerging. Because of the
species-similarity of the ANP-molecules, no specific ve-
terinary test had to be developed and a human radio-im-
munoassay (RIA) has been validated in dogs as predic-
ting factor for survival (Greco et al., 2003). An ANP
cut-off value of 25 pg/mL shows a high specificity and
sensitivity for identifying dogs with heart diseases (Hori
et al., 2011). In this study, a positive correlation be-
tween the ANP concentration and the left atrial-to-
aortic root diameter could be demonstrated, which
confirms that natriuretic peptides are released in cases
of atrial stretch (Shionoria-ANP, Shionogi Co, Osaka,
Japan). A similar correlation has been found in cats
with cardiomyopathy (Hori et al., 2008). 
The (possible) use of natriuretic peptides in equine
veterinary medicine 
As stated above, no specific equine BNP or NT-
proBNP test is yet available and no equine specific half-
life has been determined. Therefore, equine biomarker
studies are limited to the measurement of atrial natriu-
retic peptides with human assays. Gehlen et al. (2007)
and Trachsel et al. (2011) have already determined nor-
mal values for horses (15.6–26.4 pg/mL and 7.2–34
pg/mL) using two different human radioimunoassays
(RIA S2011 Peninsula Laboratories, San Carlos, USA;
RIA RK-005-06 ANP-α, Phoenix Pharmaceuticals Inc.),
and found a positive correlation between the ANP con-
centration and left atrial enlargement. 
In contrast to human and small animal veterinary
medicine, the extra-cardiac influences on natriuretic
peptides have been poorly investigated in horses. An
important effect of exercise has been described (Kok-
konen, 2002). In this study, the maximum ANP and
NT-proANP values were reached respectively 5 and 30
minutes after exercise, and both peptides remained
high until 60 minutes post-exercise. In anticipation of
further studies, samples should therefore not be taken
after exercise. Sample handling and stability of the
molecules should also be taken into account. Stability
studies conducted in human medicine have not revea-
led any clear standard sampling technique (Nelesen et
al., 1992; Buckley et al., 1999; Zolty et al., 2008).
Since no stability studies have been established for
equine ANP and NT-proANP, human data are often ex-
trapolated (Gehlen et al., 2007; Trachsel et al., 2011).
However, this should always be done with caution,
since species differences do exist. Therefore, details of
sample handling and storage are imperative for the cor-
rect interpretation of the results. Reliable results can be
obtained if aprotinin (a proteinase-inhibitor) is added to
blood EDTA (ethylenediaminetetraacetic acid) samples
and centrifuged at 4°C within 30 minutes. Plasma sto-
rage at -80°C is preferred until the assay is performed.
Since significant ANP degradation has been shown in
samples stored at -80°C for seven days, plasma samples
should be assayed immediately or within a few days
(Nelesen et al., 1992). 
THE TROPONINS, MARKERS OF MYOCYTE IN-
JURY
Physiology and structure
Troponins are part of the contractile apparatus of
muscle tissue and can be found both in skeletal and car-
diac muscles. They form a complex consisting of three
interacting proteins: troponin I, T and C (Sandersen et
al., 2008). Expression of cardiac isoforms with unique
contractile properties is found in the heart, and is nor-
mally not present in adult skeletal muscle (Parmacek
and Solaro, 2004). However, cardiac troponin T ex-
pression has been described in regenerating skeletal
muscles in patients with skeletal myopathies (Maynard
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et al., 2000). Troponins are mainly bound to myofibrils
and only 6-8 % of cardiac troponin T (cTnT) and 2.8-
4.1 % of cardiac troponin I (cTnI) can be found in the
cytosol. Damaging cardiac myocytes primarily causes
release of the cytosolic troponin pool. At a slower rate,
the structurally bound troponins are released, which
sustains the troponin elevation (Maynard et al., 2000).
The concentrations begin to rise 4-8 hours after ische-
mic injury until a peak is found after 12-24 hours. The
levels of cTnT and cTnI remain raised for 10-14 days
and 7-10 days, respectively.
The use of cardiac troponins in human and small
animal veterinary medicine
The primary role of cardiac troponin testing in humans
is the diagnosis of acute myocardial infarction (AMI). In
the last decade, troponins have replaced the less sensitive
lactate dehydrogenase (LDH) and creatine kinase-myo-
cardial band (CK-MB) isoenzymes. Not only are tropo-
nins more specific, their elevations remain longer, making
them (besides NT-proBNP) an excellent biomarker for the
detection of AMI (Maynard et al., 2000; Wells and Slee-
per, 2008). Currently, cTnT is mostly used in human cli-
nical practice. However, cTnI is comparable in diagnos-
tic and prognostic efficacy. Some authors even claim
cTnI superiority in cases of renal impairment and skele-
tal muscle damage, since cTnT specificity for cardiac
muscle may not be absolute (Maynard et al., 2000). The
use of the newer fourth generation cTnT assays could pos-
sibly limit cross reactivity in patients with renal disease.
However, primary skeletal muscle disease could still
cause false positive results (Jaffe et al., 2011).
In contrast to natriuretic peptides, the cardiac tro-
ponin structure is very conserved across species, which
indicates that human assays can be utilized in different
animals (O’brien et al., 1998). In dogs, reference values
for cTnI have already been established using a human
immunoassay (Acces Accu TnI Assay Beckman Coul-
ter, Inc., Fullerton, CA) and a human point-of-care
cTnI analyzer (i-STAT 1 handheld clinical analyzer,
Heska Corporation, Loveland, CO) (Oyama and Sis-
son, 2004; Payne et al., 2011). An increase in cTnI has
been reported in dogs with cardiomyopathy, subval-
vular aortic stenosis, mitral valve disease and cardiac
causes of respiratory distress (Oyama and Sisson, 2004;
Linklater et al., 2007; Bakirel and Gunes, 2009). Si-
milar studies in cats have described the rise of cTnI in
cats with cardiac dyspnea (Herndon et al., 2008). In
comparison with cTnI, cardiac troponin T seems less
sensitive for the diagnosis of cardiac diseases in dogs.
The exact reason is still unknown, but Linklater et al.
(2007) suggested that the smaller size of cTnI (mole-
cular weight: 22 000 Da) could lead to an easier release
of this molecule from the tropomyosin complex than
the bigger cTnT protein (molecular weight: 40 000
Da). This size difference could also explain the higher
values of cTnT in patients with renal failure, since the
renal clearance of the large cTnT is more compro-
mised (Payne et al., 2011). 
The use of troponins in equine veterinary medicine 
Currently, cardiac troponin I is the only cardiac bio-
marker which has been successfully used in equine ve-
terinary practice for the evaluation of myocardial da-
mage. Reference values have been established with
different assays, and recently, the equine cTnI half-time
has been determined.
A mean serum cTnI concentration of 0.047 ± 0.085
ng/mL has been reported in Thoroughbred horses with
the Dimension Heterogeneous Immunoassay Module
(Siemens, Newark, DE) (Phillips et al., 2003). The
same breed was studied by Begg et al. (2006), in which
serum and plasma cTnI concentrations under the de-
tection limit (<0.15 ng/mL) were found in all healthy
horses using a commercial assay (ADVIA Centaur
cTnI assay, Bayer Corporation, Pitssburg, PA, USA).
In a more recent study, a point-of-care analyzer (i-
STAT 1, Heska Corp, Loveland, Colorado) was com-
pared with a Beckman Access Immunoassay (Ohio State
University Medical Center Reference Laboratory, Co-
lumbus, Ohio), achieving plasma concentrations from
0.0-0.06 ng/mL for normal healthy horses of different
breeds (Kraus et al., 2010). 
One should keep in mind that reference values can
vary among different assays and laboratories. Thus, a
sample from a horse with cardiac problems should al-
ways be compared with assay-specific reference va-
lues. As the half-life is 0.47h in horses, a persistent high
cTnI value correlates with ongoing myocardial da-
mage (Kraus et al., 2011). This short half-life also in-
fluences the optimal time for determining maximal
elevations of cTnI. In theory, the optimal sampling
time is 1-2h after a suspected maximal increase of
cTnI. Similar to ANP, exercise results in an increase of
cTnI (Nostell and Hägström, 2008). Not only the time
of sampling but also sample handling can affect results.
Since sample stability depends on the assay antibody
configuration, sample type and handling should be per-
formed according to the manufacturer’s instructions
(Tate and Panthegini, 2008). Abbot Laboratories for
example recommends centrifugation of serum samples
(after complete clot formation) at 2500-3000 g for 10 mi-
nutes if testing is delayed for more than eight hours. Ac-
cording to these instructions, samples can be stored up
to 72 hours at 2-8°C and up to 30 days when frozen at
a maximum temperature of -10°C  (Manual of the Ar-
chitect STAT troponin I system, Abbott Laboratories,
Abbott Park, Illinois).
If all these factors are taken into consideration,
cTnI concentration can be used in daily equine practice
for the detection of myocardial damage. In the litera-
ture, the use of cTnI has been increasingly described in
horses, and retrospective studies show positive asso-
ciations between an increase in cTnI  and the degree of
cardiac damage at necropsy (Divers et al., 2009; Kraus
et al., 2010). In some case reports, this increase is ex-
tremely high. In a study by Schwarzwald et al. (2003),
a cTnI concentration of 404 ng/mL was measured
(ADVIA Centaur cTnI assay, Bayer Corporation, Pitts-
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burgh PA) in a horse with multiform ventricular ta-
chycardia. An even higher value (816 ng/mL) has been
reported in a horse with lasalocid intoxication (De-
cloedt et al., 2012). 
In contrast to human medicine, the cardiac troponin
T molecule has a lower diagnostic value in horses. In
one study, a human quantitative (Enzym Linked Im-
munosorbent Assay from Boehringer Mannheim) and
qualitative assay (Trop T Sensitive Rapid Assay, Roche
Diagnostics, Mannheim, Germany) were used (Gehlen
et al., 2006). Similar to cTnI, all of the healthy horses
had normal values under the limit of detection (<0.06
ng/mL). A significantly higher cTnT value was found
in horses with severe valve insufficiencies and cardiac
dilatation. No significant increase could be demon-
strated in horses with moderate valve insufficiencies
without cardiac dilatation. Another important result
was the surprisingly high cTnT value in 11 horses with
atypical myopathy (Gehlen et al., 2006). Since atypi-
cal myopathy causes extreme muscle damage, a cross
reaction between myocardial and skeletal cTnT could
explain these high values. However, cardiac damage
with elevation of cTnI has also been described in pa-
tients with atypical myopathy (Verheyen et al., 2012).
A high cTnT value was also found in a horse with re-
nal failure. Although it concerned only one horse, the
case highlights the importance of renal clearance when
interpreting cTnT elevations. Cardiac troponin T has
also been measured in horses with atrial fibrillation be-
fore and after transvenous electrical cardioversion
(Mcgurrin et al., 2008). Since all concentrations were




The normal physiology of the renin-angiotensin-
aldosterone system (RAAS) is shown in Figure 2. Its
main function is the monitoring of blood flow, pressure,
oxygen and Na+ concentrations (Muñoz et al., 2010).
In response to a decrease in one of these parameters, re-
nin is released from the juxtaglomular apparatus in the
kidney, which transforms the circulating angiotensi-
nogen into the biologically inert angiotensin I. Subse-
quently, angiotensin I is cleaved by the angiotensin
converting enzyme (ACE) into the biologically active
angiotensin II. This has various effects, including al-
dosterone secretion, which increases blood flow and
blood pressure by stimulating Na+ reabsorption and
vasoconstriction (Weber, 2001).
Aldosterone release in horses with cardiac pro-
blems
In case of cardiac failure, the decreased arterial fil-
ling activates the RAAS, which raises the aldosterone
concentration. In response to this aldosterone release,
water retention increases for the maintenance of the
blood flow. Unfortunately, this volume expansion exa-
cerbates diastolic wall stress and increases afterload,
which further deteriorates the already reduced ventri-
cular function (Muñoz et al., 2010). 
The correlation between aldosterone concentration
and cardiac disease has already been observed in humans
and dogs (Böhm et al., 2011; Haggstrom et al., 1997).
Unfortunately, aldosterone failed as guidance molecule
for the treatment of heart failure. Only one study has
been performed in horses with cardiac disease, in which
a significant difference in aldosterone concentration be-
tween healthy horses and horses with left atrial and left
ventricular enlargement was found (Gehlen et al., 2008).
However, no specific cut-off value for severity of heart
valve diseases was derived, emphasizing the need for
further research. 
Besides cardiac disease, many non-cardiac factors,
such as sodium intake, exercise and circadian rhythm,
influence aldosterone concentration (Guthrie et al.,
1982; Harris, 1993). In humans, a diurnal aldosterone
rhythm has been determined with maximal and mini-
mal values round 08:00h am and 02:00h am, respecti-
vely (Chiang et al., 1994). Such a diurnal variation was
Figure 2. Scheme of the normal renin-angiotensin-
aldosterone-system (RAAS). Low blood flow, blood pres-
sure, sodium absorption or arterial blood PO2 cause ac-
tivation of the RAAS with release of renin and finally the
production of aldosterone and vasopressin (adapted from
Muñoz et al., 2010).
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also noted in a study in horses by Jansson et Dahlborn,
1999. However, the highest values were reported during
the evening and in the night. Human and equine aldos-
terone are identical, thus a human radio-immunoassay
can be used to measure aldosterone concentrations in
horses (Harris, 1993). Besides sampling time, sample
handling and storage should also taken into account in
clinical practice. Aldosterone plasma and serum samples
were stable for 120h at 4°C in one study (Evans et al.,
2001). However, individual laboratory recommendations
should always be followed.
CONCLUSION
Cardiac biomarkers are intensively used in human
and small animal veterinary medicine for the diagnosis
and prognosis of heart diseases. This trend will further
develop in equine medicine and stimulates equine spe-
cific studies and the development of assays. Currently,
only cardiac troponin I can be used in equine clinical
practice for the diagnosis of myocardial damage, thereby
replacing the less specific LDH and CK-MB iso-enzy-
mes. In the future, natriuretic peptides will become more
important to estimate the diagnosis and prognosis of
heart diseases in horses. 
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PROGRESS MAKES
THE DIFFERENCE
WEGENS UITBREIDING VAN ONS MULTIDISCIPLINAIRE TEAM, ZIJN WIJ OP ZOEK NAAR EEN:
MEDEWERKER TECHNICAL SUPPORT POULTRY 
O.B.V. EEN FULLTIME DIENSTVERBAND
FUNCTIE
Technische ondersteuning van ons volledige productengamma, waaronder wij verstaan:
t )FU WFSUBMFO WBO UFDIOJTDIF FO XFUFOTDIBQQFMJKLF JOGPSNBUJF OBBS QSBLUJKLHFSJDIUF FOPG
 DPNNFSDJÑMF UFLTUFO UFO CFIPFWF WBO PO[F WFSLPPQ FO NBSLFUJOHNFEFXFSLFST JO CJOOFO FO CVJUFOMBOE
t *OGPSNBUJFWPPS[JFOJOH BBO LMBOUFO FO EJTUSJCVUFVST BMTNFEF IFU PQMPTTFO WBO QSBLUJTDIF WSBBHTUVLLFO
t )FU IPVEFO WBO QSFTFOUBUJFT WPPS DPMMFHBT EJFSFOBSUTFO FO WFFIPVEFST
t )FU WPMHFO WBO EF POUXJLLFMJOHFO JO EF WFFIPVEFSJK PQ &VSPQFFT OJWFBV FO JOUFSOF DPNNVOJDBUJF FO JOGPSNBUJFWPPS[JFOJOH IJFSPNUSFOU
PROFIEL
t %JFSFOBSUT NFU FOLFMF KBSFO QSBLUJKLFSWBSJOH JO EF QMVJNWFFIPVEFSJK
t (PFEF CFIFFSTJOH WBO .4 0óDF 	8PSE 1PXFS 1PJOU FO &YDFM

t 6JUTUFLFOEF CFIFFSTJOH WBO /FEFSMBOETF FO &OHFMTF UBBM JO XPPSE FO HFTDISJGU
t &FO FOUIPVTJBTUF UFBNQMBZFS NFU HPFEF TPDJBMF FO DPNNVOJDBUJFWF WBBSEJHIFEFO
t $SFBUJWJUFJU FO BOBMZUJTDI EFOLWFSNPHFO PN WFSXPSWFO JO[JDIUFO UF WFSUBMFO OBBS EF EBHFMJKLTF QSBLUJKL
TEVENS ZIJN WIJ OP ZOEK NAAR EEN:
QUALIFIED PERSON FOR  PHARMACOVIGILANCE (QPPV)
FUNCTIE
6 CFOU WFSBOUXPPSEFMJKL WPPS EF EJFSHFOFFTNJEEFMFOCFXBLJOH JO CJOOFO FO CVJUFOMBOE NFU BMT LFSOUBLFO
t 7FS[BNFMFO BOBMZTFSFO JOUFSQSFUFSFO FO UJKEJH SBQQPSUFSFO BBO CFWPFHEF PWFSIFJETJOTUBOUJFT WBO WFSNPFEFMJKLF CJKXFSLJOHFO FO BOEFSF POHFXFOTUF FòFDUFO
t 4DISJKWFO WBO OBUJPOBMF FO JOUFSOBUJPOBMF QFSJPEJFLF WFJMJHIFJETSBQQPSUBHFT FO CFTUVEFSFO FO BOBMZTFSFO WBO XFUFOTDIBQQFMJKLF MJUFSBUVVS
t $PNNVOJDBUJF NFU PWFSIFEFO FO EF &VSPQFBO .FEJDJOFT "HFODZ PWFS GBSNBDPWJHJMBOUJFHFSFMBUFFSEF [BLFO
t 4JHOBBMEFUFDUJF FO DPOUJOV FWBMVFSFO WBO EF ASJTLCFOFöUCBMBOT WBO PO[F EJFSHFOFFTNJEEFMFO
t 0OEFSIPVEFO WBO IFU LXBMJUFJUTTZTUFFNNCU GBSNBDPWJHJMBOUJFQSPDFEVSFT
t 5PF[JDIU PQ IFU BGTMVJUFO WBO GBSNBDPWJHJMBOUJF PWFSFFOLPNTUFO NFU DPNNFSDJÑMF QBSUOFST
t 5SBJOFO WBO 	WFSLPPQ
NFEFXFSLFST NCU SFMFWBOUF GBSNBDPWJHJMBOUJFBTQFDUFO
PROFIEL
t %JFSFOBSUT NFU FOJHF QSBLUJKLFSWBSJOH 
t #JK WPPSLFVS 	XFSL
FSWBSJOH PQ IFU HFCJFE WBO GBSNBDPWJHJMBOUJF
t (PFEF CFIFFSTJOH WBO .4 0óDF 	8PSE 1PXFS 1PJOU FO &YDFM

t 6JUTUFLFOEF CFIFFSTJOH WBO /FEFSMBOETF FO &OHFMTF UBBM JO XPPSE FO HFTDISJGU
t (PFEF TPDJBMF FO DPNNVOJDBUJFWF WBBSEJHIFEFO
t 6 CFOU BOBMZUJTDI FO LXBMJUFJUTCFXVTU
WIJ BIEDEN
t &FO VJUEBHFOEF FO WFFM[JKEJHF GVODUJF
t &FO JOTQJSFSFOEF XFSLPNHFWJOH
t (PFEF QSJNBJSF FO TFDVOEBJSF BSCFJETWPPS[JFOJOHFO
INFORMATIE
7PPS NFFS JOGPSNBUJF PWFS EF GVODUJF .FEFXFSLFS 5FDIOJDBM 4VQQPSU 1PVMUSZ LVOU V DPOUBDU PQOFNFO NFU8JKOBOE EF #SVJKO "MHFNFFO %JSFDUFVS &YUFSOF ;BLFO WBO %PQIBSNB
)PMEJOH #7 FNBJM XEFCSVJKO!EPQIBSNBDPN UFMFGPPOOVNNFS   	
   
7PPS NFFS JOGPSNBUJF PWFS EF GVODUJF 2VBMJöFE 1FSTPO GPS 1IBSNBDPWJHJMBODF LVOU V DPOUBDU PQOFNFO NFU *SNB .JEEFMIPG .BOBHJOH %JSFDUPS WBO %PQIBSNB 3FTFBSDI #7
FNBJM JNJEEFMIPG!EPQIBSNBDPN UFMFGPPOOVNNFS   	
   
7PPS VJUHFCSFJEF JOGPSNBUJF PWFS PO[F PSHBOJTBUJF WFSXJK[FO XJK V OBBS PO[F XFCTJUF XXXEPQIBSNBDPN
.PDIU V CFMBOHTUFMMJOH IFCCFO WPPS ÏÏO WBO EF WBDBUVSFT FO IFSLFOU V [JDI JO IFU CJKCFIPSFOEF QSPöFM EBO [JFO XJK VX TPMMJDJUBUJF UBW 7JWJBO $PVXFOCFSH
BGEFMJOH 1FSTPOFFMT[BLFO 	FNBJM WDPVXFOCFSH!EPQIBSNBDPN
 HSBBH CJOOFO  XFLFO OB QVCMJDBUJFEBUVN QFS FNBJM UFHFNPFU PG PQ POEFSTUBBOE BESFT
%PQIBSNB )PMEJOH UBW 7JWJBO $PVXFOCFSH ;BMNXFH   79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Dopharma B.V. is een dynamisch bedrijf dat op basis van eigen kennisbronnen veterinaire 
farmaceutische producten registreert en produceert. Zowel in het binnen- als buitenland biedt 
Dopharma een uitgebalanceerd pakket diergeneesmiddelen aan. Dopharma produceert 95% 
van haar diergeneesmiddelen zelf, op eigen moderne GMP gecertificeerde productielijnen, 
waaronder een steriele plant. Voor een snelle distributie in Nederland heeft Dopharma een 
eigen expeditie afdeling. Binnen Dopharma Research B.V. worden registratiestudies verricht. 
Hiertoe beschikt Dopharma Research over 2 laboratoria en een proefstal, waar de 
onderzoeken worden uitgevoerd in overeenstemming met de GLP principes.
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